This is a Phase 2, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Belvarafenib in patients with BRAF-altered primary brain tumors (Cohort 1) and metastatic brain tumors (Cohort 2). Eligible patients are those with a confirmed BRAF alteration identified by next-generation sequencing (NGS).
Patients who meet the eligibility criteria will receive a detailed explanation of the study, including its purpose, procedures, potential benefits, and risks. Only patients who voluntarily provide written informed consent will be enrolled.
All enrolled patients will receive Belvarafenib monotherapy at a dose of 450 mg twice daily (BID). The study drug will be taken orally within 30 minutes after meals with at least 200 mL of water, preferably at approximately 12-hour intervals each day. One treatment cycle is defined as 28 consecutive days of continuous dosing without a planned treatment break. Patients will receive treatment for six cycles (approximately six months) as the initial treatment period. Treatment may be extended or discontinued earlier at the investigator's discretion based on clinical benefit, disease status, and tolerability.
During the study, patients will undergo regular clinical evaluations, including physical examinations, vital sign assessments, laboratory tests, and monitoring for adverse events. Radiologic assessments using MRI and/or CT will be performed at scheduled intervals to evaluate tumor response and disease progression. The study aims to determine whether Belvarafenib can control tumor growth, delay disease progression, and improve clinical outcomes in patients with BRAF-altered brain tumors.
If treatment-related toxicities occur, dose reductions are permitted according to the protocol. The dose may be reduced from 450 mg BID to 300 mg BID, and subsequently to 200 mg BID, if clinically indicated. Temporary treatment interruption may also be implemented until toxicity resolves. If unacceptable toxicity persists despite dose modification, treatment will be permanently discontinued.
Study treatment may be discontinued if any of the following occurs: confirmed disease progression, unacceptable toxicity, withdrawal of informed consent, inability to comply with the study protocol, receipt of other anticancer therapies that may interfere with study outcomes, or if the investigator determines that continued treatment is no longer in the patient's best interest. However, if radiologic disease progression is observed but the investigator determines that the patient continues to derive clinical benefit, treatment beyond progression may be considered after discussion with the sponsor, with appropriate documentation of the rationale.
After discontinuation of study treatment, patients will receive the most appropriate subsequent management, including best supportive care (BSC) or other anticancer therapies, as determined by the treating investigator. Follow-up assessments will continue according to the study protocol.
The primary objective of this study is to evaluate the efficacy of Belvarafenib in patients with BRAF-altered primary and metastatic brain tumors, while also assessing its safety profile. The results of this study are expected to provide important clinical evidence supporting the development of new treatment strategies for patients with BRAF-altered brain tumors.

Start Date15 Jun 2026

Sponsor / Collaborator

Samsung Medical Center

NCT07449754

/ RecruitingPhase 2

A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects.
Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.

Start Date12 Feb 2026

Sponsor / Collaborator

Hanmi Pharmaceutical Co., Ltd.

ISRCTN47564876

/ CompletedPhase 1

A phase I, single-dose, randomized, crossover, relative bioavailability and food-effect study and phase I, single-dose, fixed-sequence, crossover, pH-effect study of belvarafenib (GDC-5573) in healthy subjects

Start Date20 Sep 2022

Sponsor / Collaborator-

100 Clinical Results associated with Belvarafenib

100 Translational Medicine associated with Belvarafenib

100 Patents (Medical) associated with Belvarafenib

Literatures (Medical) associated with Belvarafenib

01 Aug 2025·Nature Chemical Biology

Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance

Article

Author: Su, Wenjing ; Ji, Zhiheng ; Fang, Yue ; Li, Mingyi ; Fan, Zuyan ; Lu, Huasong ; Sun, Jun ; Li, Wen ; Ding, Junjun ; Jiang, Zhaodi ; Luo, Mengxin ; Zhou, Jing ; Xie, Wei ; Shi, Xiaoxian ; Ma, Weirui ; Ding, Zhifan ; Tan, Caiwei

RAF protein kinases are major RAS effectors that function by phosphorylating MEK. Although all three RAF isoforms share a conserved RAS binding domain and bind to GTP-loaded RAS, only ARAF uniquely enhances RAS activity. Here we uncovered the molecular basis of ARAF in regulating RAS activation. The disordered N-terminal sequence of ARAF drives self-assembly, forming ARAF-RAS condensates tethered to the plasma membrane. These structures concentrate active RAS locally, impeding NF1-mediated negative regulation of RAS, thereby fostering receptor tyrosine kinase (RTK)-triggered RAS activation. In RAS-mutant tumors, loss of the ARAF N terminus sensitizes tumor cells to pan-RAF inhibition. In hormone-sensitive cancers, increased ARAF condensates drive endocrine therapy resistance, whereas ARAF depletion reverses RTK-dependent resistance. Our findings delineate ARAF-RAS protein condensates as distinct subcellular structures sustaining RAS activity and facilitating oncogenic RAS signaling. Targeting ARAF-RAS condensation may offer a strategy to overcome drug resistance in both wild-type and mutant ARAF-mediated scenarios.

20 Feb 2025·BLOOD

BRAFV600E induces key features of LCH in iPSCs with cell type–specific phenotypes and drug responses

Article

Author: Halbritter, Florian ; Ben Soussia-Weiss, Philipp ; van Midden, Wouter ; Distel, Martin ; Hutter, Caroline ; Taschner-Mandl, Sabine ; Schwentner, Raphaela ; Sturtzel, Caterina ; Pötschger, Ulrike ; Hafemeister, Christoph ; Eder, Sebastian K. ; Simonitsch-Klupp, Ingrid ; Rados, Magdalena ; Abagnale, Giulio

Abstract:

Langerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder defined by tumorous lesions containing CD1a+/CD207+ cells. Two severe complications of LCH are systemic hyperinflammation and progressive neurodegeneration. The scarcity of primary samples and lack of appropriate models limit our mechanistic understanding of LCH pathogenesis and affect patient care. We generated a human in vitro model for LCH using induced pluripotent stem cells (iPSCs) harboring the BRAFV600E mutation, the most common genetic driver of LCH. We show that BRAFV600E/WT iPSCs display myelomonocytic skewing during hematopoiesis and spontaneously differentiate into CD1a+/CD207+ cells that are similar to lesional LCH cells and are derived from a CD14+ progenitor. We show that BRAFV600E modulates the expression of key transcription factors regulating monocytic differentiation and leads to an upregulation of proinflammatory molecules and LCH marker genes early during myeloid differentiation. In vitro drug testing revealed that BRAFV600E-induced transcriptomic changes are reverted upon treatment with mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKis). Importantly, MAPKis do not affect myeloid progenitors but reduce only the mature CD14+ cell population. Furthermore, iPSC-derived neurons (iNeurons) cocultured with BRAFV600E/WT iPSC-derived microglia-like cells, differentiated from iPSC-derived CD34+ progenitors, exhibit signs of neurodegeneration with neuronal damage and release of neurofilament light chain. In summary, the iPSC-based model described here provides a platform to investigate the effects of BRAFV600E in different hematopoietic cell types and provides a tool to compare and identify novel approaches for the treatment of BRAFV600E-driven diseases.

20 Aug 2024·JOURNAL OF VIROLOGY

The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms

Article

Author: Wilken, Lucas ; Rimmelzwaan, Guus F. ; Elbahesh, Husni ; Rimmelzwaan, Guus F

ABSTRACT:

Zika virus (ZIKV) is a re-emerging mosquito-borne flavivirus that has been associated with congenital neurological defects in fetuses born to infected mothers. At present, no vaccine or antiviral therapy is available to combat this devastating disease. Repurposing drugs that target essential host factors exploited by viruses is an attractive therapeutic approach. Here, we screened a panel of clinically approved small-molecule kinase inhibitors for their antiviral effects against a clinical isolate of ZIKV and thoroughly characterized their mechanisms of action. We found that the Raf kinase inhibitors Dabrafenib and Regorafenib potently impair the replication of ZIKV, but not that of its close relative dengue virus. Time-of-addition experiments showed that both inhibitors target ZIKV infection at post-entry steps. We found that Dabrafenib, but not Regorafenib, interfered with ZIKV genome replication by impairing both negative- and positive-strand RNA synthesis. Regorafenib, on the other hand, altered steady-state viral protein levels, viral egress, and blocked NS1 secretion. We also observed Regorafenib-induced ER fragmentation in ZIKV-infected cells, which might contribute to its antiviral effects. Because these inhibitors target different steps of the ZIKV infection cycle, their use in combination therapy may amplify their antiviral effects which could be further explored for future therapeutic strategies against ZIKV and possibly other flaviviruses.

IMPORTANCE:

There is an urgent need to develop effective therapeutics against re-emerging arboviruses associated with neurological disorders like Zika virus (ZIKV). We identified two FDA-approved kinase inhibitors, Dabrafenib and Regorafenib, as potent inhibitors of contemporary ZIKV strains at distinct stages of infection despite overlapping host targets. Both inhibitors reduced viral titers by ~1 to 2 log 10 (~10-fold to 100-fold) with minimal cytotoxicity. Furthermore, we show that Dabrafenib inhibits ZIKV RNA replication whereas Regorafenib inhibits ZIKV translation and egress. Regorafenib has the added benefit of limiting NS1 secretion, which contributes to the pathogenesis and disease progression of several flaviviruses. Because these inhibitors affect distinct post-entry steps of ZIKV infection, their therapeutic potential may be amplified by combination therapy and likely does not require prophylactic administration. This study provides further insight into ZIKV-host interactions and has implications for the development of novel antivirals against ZIKV and possibly other flaviviruses.

News (Medical) associated with Belvarafenib

10 Jul 2026

·www.hanmipharm.com

Hanmi R&D Aims to Close the Treatment Gap in Melanoma as Belvarafenib Advances Through Phase 2 Trial

Hanmi Presents Phase 2 Trial Design and Clinical Development Progress of Belvarafenib at Korean Cancer Association Annual Meeting Meaningful antitumor efficacy demonstrated in patients with NRAS-mutant melanoma, for which no approved therapies exist in Korea or globally Seongjung Kim, Researcher in Hanmi’s Clinical Development Team (center), presents a poster on the Phase 2 clinical development program of the oral targeted anticancer agent Belvarafenib to attendees at the 52nd Korean Cancer Association Annual Meeting (KCA 2026) on June 26. Seongjung Kim, Researcher in Hanmi’s Clinical Development Team (center), presents a poster on the Phase 2 clinical development program of the oral targeted anticancer agent Belvarafenib to attendees at the 52nd Korean Cancer Association Annual Meeting (KCA 2026) on June 26. (July 10, 2026) Hanmi is advancing Korea's first domestic Phase 2 clinical trial of Belvarafenib, a novel oral targeted anticancer therapy for melanoma, a malignant skin cancer. Patient enrollment is currently underway for individuals who meet the trial eligibility criteria. If successfully commercialized, Belvarafenib is expected to offer a new treatment option for patients with NRAS-mutant melanoma who currently have limited treatment options. Hanmi Pharmaceutical, a core operating company of Hanmi Science, announced on July 10 that it presented the Phase 2 trial design and development progress of Belvarafenib in a poster session at the 52nd Korean Cancer Association Annual Meeting (KCA 2026), held from June 25 to 26 at Grand InterContinental Seoul Parnas in Gangnam, Seoul. Originally developed by Hanmi, Belvarafenib is an oral targeted anticancer agent designed to inhibit RAF and RAS gene mutations within the MAPK pathway, which is involved in tumor cell growth and proliferation. Melanoma is a difficult-to-treat cancer characterized by limited treatment options and a high risk of recurrence, with most currently available therapies supplied by foreign pharmaceutical companies. In particular, NRAS-mutant melanoma has been reported to exhibit greater tumor invasiveness and metastatic potential than melanoma in general, as well as shorter overall survival. In a global Phase 1 clinical trial conducted in patients with solid tumors, Belvarafenib demonstrated meaningful antitumor activity in patients harboring NRAS and BRAF mutations. Based on these findings, further clinical development is currently underway in Korea for patients with NRAS-mutant melanoma. NRAS-mutant melanoma remains an area of high unmet medical need, with no approved standard-of-care therapies available worldwide. In current clinical practice, Belvarafenib is being administered on a limited basis to certain patients under treatment-purpose use approval (compassionate use). The ongoing domestic Phase 2 trial is being conducted as a multicenter, single-arm study to evaluate the efficacy and safety of a combination therapy consisting of Belvarafenib and cobimetinib, a MEK inhibitor, in patients with locally advanced or metastatic melanoma harboring NRAS mutations. The combination therapy of Belvarafenib and cobimetinib is regarded as a treatment strategy capable of overcoming the mechanistic limitations of existing BRAF inhibitor？MEK inhibitor combination therapies while offering the potential for sustained clinical benefit across a broader range of genetically defined patient populations. Since enrollment of the first patient in February, the Phase 2 trial has been progressing smoothly across 10 clinical sites nationwide, with additional eligible patients continuing to be enrolled. Hanmi plans to complete enrollment of a total of 45 patients by 2027 and, based on the Phase 2 results, file for conditional approval in Korea in 2028. Belvarafenib was selected for the the MFDS "Giljabi (Navigator)" program, an innovative product commercialization support initiative introduced last year to accelerate the development of promising innovative drug candidates with high social urgency and commercialization potential. The program provides systematic support for rapid commercialization, including assistance in preparing regulatory submissions linked to the GIFT expedited review program and advance reviews of documentation standards when necessary. Moon Hee Lee, Head of Clinical Team at Hanmi, said, “Through the Phase 2 trial of Belvarafenib, we are focused on systematically evaluating efficacy and safety in patients with NRAS-mutant melanoma and we hope this clinical trial will offer a new treatment opportunity.” She added, “As patient enrollment continues, we hope this clinical trial will provide a new treatment opportunity for patients whose treatment options remain limited.”

Phase 2Phase 1Clinical Result

19 Feb 2026

·www.hanmipharm.com

Hanmi Begins Dosing in Phase 2 Trial of Belvarafenib, a Novel Melanoma Therapy

<Oral Targeted Anticancer Agent> First patient enrolled and dosed in Phase 2 trial at a domestic university hospital on February 23 Meaningful antitumor efficacy in NRAS-mutant melanoma patients with no available therapies in Korea or globally Abdominal CT images showing changes in tumor lesions over time in a clinical trial of combination therapy with belvarafenib and cobimetinib in patients with NRAS-mutant melanoma. (February 19, 2026) For the first time in Korea, Hanmi has begun patient dosing in a domestic Phase 2 clinical trial of Belvarafenib, a novel oral targeted anticancer therapy for the treatment of melanoma, a malignant skin cancer. Hanmi Pharmaceutical, a core operating company of Hanmi Science, announced on February 19 that it enrolled the first patient and completed the first administration in a Phase 2 clinical trial evaluating Belvarafenib in patients with locally advanced or metastatic melanoma harboring NRAS mutations at a domestic university hospital on 12. Notably, the first patient was dosed in just about one month after the Ministry of Food and Drug Safety (MFDS) approved the Phase 2 investigational new drug (IND) application for Belvarafenib in January, underscoring the rapid progress of the clinical program. This Phase 2 trial is being conducted as a multicenter, single-arm study in a total of 45 patients to evaluate the efficacy and safety of a combination therapy of Belvarafenib and cobimetinib, a MEK inhibitor. Melanoma is a difficult-to-treat cancer with limited treatment options and a high risk of recurrence, and most currently available therapies are supplied by foreign pharmaceutical companies. In particular, NRAS-mutant melanoma represents an area of high unmet medical need, with poor prognosis and no approved standard-of-care therapies in Korea or globally. In current clinical practice, Belvarafenib is being administered on a limited basis to certain patients under treatment-purpose use approval (compassionate use). Dr. Young Su Noh, Head of Hanmi’s ONCO Clinical Research and Development Team, stated, “Through this Phase 2 trial, we will closely examine therapeutic efficacy in the NRAS-mutant melanoma patient population and do our utmost to execute clinical development in a more systematic and accelerated manner to deliver encouraging results.” Belvarafenib, originally developed by Hanmi Pharmaceutical, is an oral targeted anticancer agent designed to inhibit RAF and RAS gene mutations within the mitogen-activated protein kinase (MAPK) pathway, which is involved in tumor cell growth and proliferation. Based on its differentiated mechanism as a selective RAF dimer inhibitor, Belvarafenib targets tumors harboring BRAF Class II/III alterations and RAS mutations. Unlike conventional BRAF inhibitors that primarily suppress RAF monomers, Belvarafenib is designed to inhibit both BRAF and CRAF dimers, enabling it to overcome resistance issues associated with RAF dimer formation. Accordingly, the combination therapy of Belvarafenib and cobimetinib is regarded as a treatment strategy capable of overcoming the mechanistic limitations of existing BRAF monomer？MEK inhibitor combination therapies while offering potential clinical benefits across a broader range of genetically defined patient populations. Jae Hyun Park, CEO of Hanmi Pharmaceutical, said, “We remain fully committed to developing innovative new medicines that can offer new hope to cancer patients suffering without adequate treatment options,” adding, “We will dedicate every effort to ensuring that Belvarafenib can become a key treatment option that meaningfully closes the long-standing treatment gap in melanoma and other rare and intractable cancers.”

Phase 2Phase 1INDMicrobial therapy

08 Jan 2026

·www.hanmipharm.com

Hanmi to Advance Korea’s First Domestic Melanoma Therapy, Belvarafenib, Following Phase 2 Clearance

Efficacy confirmed in NRAS-mutant melanoma patients with no available treatment options Advancing new drug development through close collaboration with physicians, patients, and regulators Hanmi announced on January 8 that the Ministry of Food and Drug Safety (MFDS) has cleared the Phase 2 Investigational New Drug (IND) application for Belvarafenib, a targeted anticancer therapy. therapy of Belvarafenib and the MEK inhibitor cobimetinib in patients with locally advanced or metastatic melanoma harboring NRAS mutations. Belvarafenib, originally developed by Hanmi Pharmaceutical, is an oral targeted anticancer agent that inhibits RAF and RAS mutations within the mitogen-activated protein kinas signaling (MAPK) pathway, which plays a key role in tumor cell growth and proliferation. In particular, Belvarafenib targets NRASmut melanoma and BRAF class II or class III alteration-positive tumors based on its differentiated mechanism as a selective RAF dimer inhibitor. Unlike conventional BRAF inhibitors that primarily suppress RAF monomers, Belvarafenib is designed to inhibit both BRAF and CRAF dimers, enabling it to overcome associated resistance to the RAF dimer formation. Accordingly, the combination therapy of Belvarafenib and cobimetinib is regarded as a treatment strategy capable of overcoming the mechanistic limitations of existing BRAF monomer？MEK inhibitor combination therapies, while offering potential clinical benefits across a broader range of genetically defined patient populations. In a previously completed Phase 1 clinical trial involving patients with solid tumors, the combination therapy of Belvarafenib and cobimetinib demonstrated a favorable safety profile and preliminary efficacy. Notably, meaningful antitumor activity was observed in patients with NRAS and BRAF mutations, providing a strong rationale for further clinical development. , “We expect Belvarafenib to establish itself as a next-generation innovative therapy in rare and unrescatable cancers with limited treatment options, including melanoma,” adding, “We will work closely with domestic physicians ◆ Selected for MFDS Guidance Program for Innovative Products…End-to-End Support for Development and Approval

Phase 1INDPhase 2Microbial therapyClinical Result

100 Deals associated with Belvarafenib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 2	South Korea	Hanmi Pharmaceutical Co., Ltd.	12 Feb 2026
NRAS Mutant Melanoma	Phase 2	South Korea	Hanmi Pharmaceutical Co., Ltd.	12 Feb 2026
Metastatic Solid Tumor	Phase 2	United States	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	China	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Japan	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Australia	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Belgium	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Brazil	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Canada	Hoffmann-La Roche, Inc.	18 Jan 2021
Metastatic Solid Tumor	Phase 2	Denmark	Hoffmann-La Roche, Inc.	18 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04589845 (TAPISTRY, ESMO2024)	Phase 2	Metastatic Solid Tumor \| Solid tumor \| Non-Small Cell Lung Cancer BRAF class II	-	Belvarafenib 400 mg	nwnlqofbbi(hdefmwjsqm) = 30 (100.0) vs 23 (95.8) of pts experienced at least one adverse event with Belvarafenib 400 mg vs Placebo spmheqhyfm (lhudvmzkuq ) View more	Negative	14 Sep 2024
NCT04589845 (TAPISTRY, ESMO2024)	Phase 2		-	Placebo		Negative	14 Sep 2024
NCT03284502 (HM-RAFI-103, ESMO 12023 \| ESMO 22023) Manual	Phase 1	BRAF mutation Solid Tumors BRAF mutation	133	Belvarafenib 300mg PO BID + Cobimetinib 20mg PO TIW	-	Positive	23 Oct 2023
NCT03284502 (HM-RAFI-103, ESMO 12023 \| ESMO 22023) Manual	Phase 1	BRAF mutation Solid Tumors BRAF mutation	133	Belvarafenib 300mg PO BID + Cobimetinib 20mg PO TIW (SC-A: BRAF fusion)	eejuxffyrh(eqerzjirgi) = qyqbclomau fbmpgmxinh (itfqqqeqzw, 68.05 - 99.83) View more	Positive	23 Oct 2023
NCT03284502 (ESMO2021) Manual	Phase 1	RAS/RAF mutation Solid Tumors NRAS Mutation \| BRAF Mutation	118	cobimetinib+belvarafenib (NRASm melanoma)	yrefhypazu(ritzwswbdt) = The most common treatment-emergent adverse events (TEAEs) were dermatitis acneiform (52.5%), diarrhea (28.0%), rash (27.1%), and increased CPK level (25.4%). mxplqrwikr (cxrqffptll )	Positive	16 Sep 2021
NCT03284502 (ESMO2021) Manual	Phase 1	RAS/RAF mutation Solid Tumors NRAS Mutation \| BRAF Mutation	118	cobimetinib+belvarafenib (BRAFm melanoma)		Positive	16 Sep 2021
NCT03284502 (ASCO2021)	Phase 1	NRAS Mutant Melanoma \| HR-positive/HER2-low Solid Tumors	32	Belvarafenib	ysrqjjetab(iimcztheju) = dezhyvqewu rebgshudzi (rfqkcnoknp )	-	28 May 2021
NCT02405065 \| NCT03118817 (ASCO2019)	Phase 1	BRAF mutation Solid Tumors	-	Belvarafenib	slzpqrwmiw(gjkhaougbh) = The most common treatment-emergent adverse events that occurred in more than 20% of patients were dermatitis acneiform kxlcfgqqrm (ynmdfqranz ) View more	Positive	26 May 2019
NCT02405065 (ASCO 12016 \| ASCO 22016) Manual	Phase 1	Solid tumor	31	Belvarafenib	qfhijhpsrg(msmkroesew) = One patient at 200mg BID experienced grade 3 skin rash oxrfioggcb (wfcizsgtaw ) View more	Positive	05 Jun 2016
AACR2015	Phase 1	Melanoma	-	HM95573	cchqqkxadi(ajfnnhidlg) = srrccqdrjl iygskgjajz (froehxdlef ) View more	-	01 Aug 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis